Astera Labs (ALAB) Stock Price Prediction: Record Q3 growth meets a shaky rebound at the moving averages
Record Q3 growth is the fundamental anchor
Astera Labs reported third-quarter 2026 revenue of $584.9 million, up 49% sequentially and 154% year over year, alongside non-GAAP EPS of $1.32, according to the company’s November 3 release. Management also guided fourth-quarter revenue to $730 million to $750 million. That is the core reason ALAB stock still has support despite the recent swing in semiconductor sentiment: revenue momentum is still accelerating, and the company said Scorpio fabric switches became its largest product family as high-volume production ramped.
BMO Capital Markets added to that narrative on November 5, initiating coverage with an outperform rating and a $375 target, saying Astera Labs is positioned as an AI networking leader. At the same time, the analyst tape is not one-way: the same week brought target cuts from some firms, while Morgan Stanley nudged its target up to $389. Stockanalysis.com shows a 25-analyst consensus target of $344.15 with a buy rating profile, but that average sits well above the current price and does not erase the spread between bullish and cautious views.
Price action: bounce, but not yet a clean trend reversal
ALAB closed at $221.64, up 8.51% over 24 hours, after trading between $191.28 and $229.94. That puts the stock just above its 7-day SMA of $218.58 and its 20-day SMA of $220.29, so the near-term bounce has recovered the short moving averages. But the 50-day SMA remains far overhead at $275.90, which tells you the intermediate trend is still damaged.
The momentum picture is mixed rather than decisive. RSI at 45.13 is neutral, not overbought. MACD is negative at -15.1283, which argues the recovery has not yet flipped into a sustained trend. The stochastic reading is firmer, with %K at 74.39 versus %D at 59.51, so short-term upside pressure is present, but the structure still looks like an oversold rebound attempt rather than a confirmed breakout.
Key levels the market is watching
The immediate pivot is $214.29. Holding above that keeps the rebound intact. Below that, immediate support comes in at $198.63, with stronger support at $175.63. On the upside, the first test is $237.29, then stronger resistance at $252.95.
That matters because the current price is sitting almost exactly on the Bollinger middle band at $220.29, with %B at 0.5149. In plain terms, ALAB is no longer stretched to the downside, but it is also not pressing the upper band at $265.70. The setup is balanced, not explosive.
Binance Futures positioning favors a bounce, but not a conviction breakout
Derivatives positioning on Binance Futures is modestly constructive. The 8-hour funding rate is neutral at 0.0000%, so traders are not paying a premium to stay long. Open interest stands at 2,530.35 contracts, with daily open interest value at $569,339, and 24-hour OI is down 15.69%, which suggests position closing or liquidation rather than fresh leverage chasing the move.
The long/short ratios lean long: global Binance accounts are 61.3% long versus 38.7% short, while top-trader accounts are 70.7% long versus 29.3% short. Taker flow is also mildly positive, with a buy/sell ratio of 1.1068. That supports the idea of active dip-buying, but the low-volume backdrop matters: the supplied volume-price regime is 0.46x versus the 5-day average, so the bounce still needs participation to validate it.
What would confirm or break the setup
A clean push through $237.29 would improve the short-term picture and open the path toward $252.95, but that move needs stronger volume than the current low-volume regime. Failure to hold $214.29 would weaken the rebound case, and a drop through $198.63 would shift attention back toward the lower support band and the possibility that the current advance was just a short-covering rally.
For now, ALAB sits between strong company-level momentum and a market structure that is still repairing itself. The earnings print and Q4 guide justify attention; the chart and futures data say the recovery is real, but not yet fully proven.